Bjorn Onfelt
Overview
Explore the profile of Bjorn Onfelt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
68
Citations
2183
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
van Ooijen H, Verron Q, Zhang H, Sandoz P, Frisk T, Carannante V, et al.
Cell Rep Methods
. 2025 Jan;
5(1):100965.
PMID: 39826552
We present an easy-to-use, disposable, thermoplastic microwell chip designed to support screening and high-resolution imaging of single-cell behavior in two- and three-dimensional (2D and 3D) cell cultures. We show that...
2.
Al Agrafi F, Gaballa A, Hahn P, Arruda L, Jaramillo A, Witsen M, et al.
Oncoimmunology
. 2024 Jul;
13(1):2379063.
PMID: 39076247
Despite the considerable progress in acute myeloid leukemia (AML) treatment, relapse after allogeneic hematopoietic stem cell transplantation (HSCT) is still frequent and associated with a poor prognosis. Relapse has been...
3.
You Y, Dunst J, Ye K, Sandoz P, Reinhardt A, Sandrock I, et al.
Nat Immunol
. 2024 Jul;
25(8):1367-1382.
PMID: 38992254
Upregulation of diverse self-antigens that constitute components of the inflammatory response overlaps spatially and temporally with the emergence of pathogen-derived foreign antigens. Therefore, discrimination between these inflammation-associated self-antigens and pathogen-derived...
4.
Hammer Q, Perica K, Mbofung R, van Ooijen H, Martin K, Momayyezi P, et al.
Cell Stem Cell
. 2024 Jul;
31(9):1376-1386.e8.
PMID: 38981470
Allogeneic cellular immunotherapies hold promise for broad clinical implementation but face limitations due to potential rejection of donor cells by the host immune system. Silencing of beta-2 microglobulin (B2M) expression...
5.
Hammer Q, Perica K, van Ooijen H, Mbofung R, Momayyezi P, Varady E, et al.
bioRxiv
. 2023 Oct;
PMID: 37873468
Allogeneic cell therapies hold promise for broad clinical implementation, but face limitations due to potential rejection by the recipient immune system. Silencing of beta-2-microglobulin ( ) expression is commonly employed...
6.
Sandoz P, Kuhnigk K, Szabo E, Thunberg S, Erikson E, Sandstrom N, et al.
Nat Commun
. 2023 Sep;
14(1):6035.
PMID: 37758698
γδ T cells play a pivotal role in protection against various types of infections and tumours, from early childhood on and throughout life. They consist of several subsets characterised by...
7.
Carannante V, Sandstrom N, Olofsson K, van Ooijen H, Hell B, Wiklund M, et al.
Methods Cell Biol
. 2023 Jul;
178:195-208.
PMID: 37516526
The development of new immunotherapeutic drugs and combinatorial strategies requires the implementation of novel methods to test their efficacy in vitro. Here, we present a series of miniaturized in vitro...
8.
Carannante V, Wiklund M, Onfelt B
Front Immunol
. 2023 Jul;
14:1135148.
PMID: 37457703
Immunotherapy is revolutionizing cancer therapy. The rapid development of new immunotherapeutic strategies to treat solid tumors is posing new challenges for preclinical research, demanding novel methods to test treatments. Such...
9.
Philippon C, Tao S, Clement D, Haroun-Izquierdo A, Kichula K, Netskar H, et al.
Blood Adv
. 2023 Jun;
7(16):4492-4504.
PMID: 37327114
The functionality of natural killer (NK) cells is tuned during education and is associated with remodeling of the lysosomal compartment. We hypothesized that genetic variation in killer cell immunoglobulin-like receptor...
10.
Haroun-Izquierdo A, Vincenti M, Netskar H, van Ooijen H, Zhang B, Bendzick L, et al.
J Immunother Cancer
. 2022 Nov;
10(11).
PMID: 36319065
Background: Natural killer (NK) cells hold great promise as a source for allogeneic cell therapy against hematological malignancies, including acute myeloid leukemia (AML). Current treatments are hampered by variability in...